Table 25Strength of evidence for intermediate health outcomes comparing adalimumab with narrow band ultaviolet B

OutcomeStudy design and numberRisk of biasConsistencyDirectnessPrecisionsStrength of Evidence
Plaque BSARCT (0)------------Insufficient
Observational (1)Medium risk of biasNADirectNA
PASIRCT (0)------------Insufficient
Observational (1)Medium risk of biasNADirectNA
PGARCT (0)------------Insufficient
Observational (1)Medium risk of biasNADirectNA
Patient assessment of diseaseRCT (0)------------Insufficient
Observational (0)------------
Individual symptomsRCT (0)------------Insufficient
Observational (0)------------

From: Appendix G, Strength of Evidence for Outcomes

Cover of Biologic and Nonbiologic Systemic Agents and Phototherapy for Treatment of Chronic Plaque Psoriasis
Biologic and Nonbiologic Systemic Agents and Phototherapy for Treatment of Chronic Plaque Psoriasis [Internet].
Comparative Effectiveness Reviews, No. 85.
Lee S, Coleman CI, Limone B, et al.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.